GO:0034384 high-density lipoprotein particle clearance: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0034384 (high-density lipoprotein particle clearance) describes the receptor-mediated removal of HDL particles from the blood and the degradation of their constituent parts.
• Cubilin (CUBN) was identified as a high-density lipoprotein receptor that mediates HDL holoparticle endocytosis in kidney proximal tubule cells.
• HDL clearance is a major determinant of plasma HDL-cholesterol levels and is regulated by miRNAs, statins, and metabolic states such as obesity.
• Reconstituted HDL therapy improves survival in mouse models of sepsis, linking HDL clearance and function to infection outcomes.
• HDL particles act as bug scavengers, binding and neutralizing bacterial components, which influences clearance and innate immunity.
• HDL and its clearance pathways are relevant to atherosclerosis, sepsis, obesity, and blood-brain barrier function.
Description
High-density lipoprotein particle clearance (GO:0034384) is the biological process by which a high-density lipoprotein (HDL) particle is removed from the bloodstream via receptor-mediated endocytosis and its constituent parts are subsequently degraded. This process is central to HDL metabolism because it determines the residence time of HDL in circulation and directly influences plasma HDL-cholesterol concentrations. Understanding HDL clearance is important for researchers studying cardiovascular disease, lipid disorders, and innate immunity, as HDL particles carry cholesterol and also interact with pathogens and inflammatory mediators. The identification of cubilin as an HDL receptor provided a molecular entry point for studying how HDL particles are internalized and catabolized. Subsequent work has shown that HDL clearance is modulated by microRNAs, pharmacological agents such as statins, and metabolic conditions including obesity. In addition, HDL clearance and function have been linked to sepsis survival in mouse models and to blood-brain barrier regulation, expanding the relevance of this GO term beyond classical lipidology.
high-density lipoprotein particle clearance At A Glance
| GO ID | GO:0034384 |
|---|---|
| GO term | high-density lipoprotein particle clearance |
| Ontology | biological_process |
| Synonym | HDL clearance |
| Major function | Receptor-mediated endocytosis and degradation of HDL particles from blood |
| Key receptor | Cubilin (CUBN) acts as a high-density lipoprotein receptor |
| Regulatory factors | miRNAs, statins, obesity status |
| Disease relevance | Atherosclerosis, sepsis, obesity, blood-brain barrier function |
What Is GO:0034384?
GO:0034384, high-density lipoprotein particle clearance, is defined as the process in which a high-density lipoprotein particle is removed from the blood via receptor-mediated endocytosis and its constituent parts are degraded. In other words, it covers the recognition, binding, internalization, and catabolic breakdown of HDL particles, leading to their elimination from circulation. This term is a biological process and is synonymous with HDL clearance.
Why Is high-density lipoprotein particle clearance Important in Cell Biology?
HDL clearance is a critical determinant of plasma HDL-cholesterol levels and overall lipoprotein metabolism, and its dysregulation has been implicated in atherosclerosis, sepsis, obesity, and blood-brain barrier dysfunction. Because HDL particles participate in reverse cholesterol transport and also scavenge bacterial components, the rate at which they are cleared affects both cardiovascular risk and innate immune responses. Studying GO:0034384 therefore provides mechanistic insight into how the body maintains HDL homeostasis and how therapeutic interventions such as statins or reconstituted HDL may alter disease outcomes.
• Controls plasma HDL-cholesterol levels by removing HDL particles from circulation.
• Cubilin-mediated HDL endocytosis provides a molecular mechanism for HDL catabolism.
• miRNAs regulate HDL metabolism, including clearance pathways.
• Statins modulate HDL metabolism and can affect clearance dynamics.
• Obesity alters HDL metabolism, potentially impacting clearance.
• HDL particles act as scavengers for bacterial components, linking clearance to infection.
• Reconstituted HDL therapy improves survival in sepsis models, highlighting clinical relevance.
• HDL and its clearance influence blood-brain barrier function.
• The antiatherogenic role of HDL depends on its metabolism, including clearance.
• Understanding HDL clearance aids development of therapies for dyslipidemia and cardiovascular disease.
What Happens During high-density lipoprotein particle clearance?
Recognition and binding of HDL particles
In simple terms: HDL particles are recognized by specific receptors on the cell surface.
The first step in HDL clearance is the recognition of HDL particles by cell-surface receptors. Cubilin (CUBN) has been identified as a high-density lipoprotein receptor that binds HDL particles, facilitating their uptake. This receptor-mediated binding is a prerequisite for subsequent internalization and degradation.
Receptor-mediated endocytosis
In simple terms: The cell engulfs the HDL particle through its membrane.
Following binding, HDL particles are internalized via receptor-mediated endocytosis. Cubilin mediates the endocytosis of HDL holoparticles, leading to their delivery into intracellular compartments. This process removes HDL from the bloodstream and targets it for catabolism.
Intracellular degradation of HDL constituents
In simple terms: Inside the cell, the HDL particle is broken down into its components.
After endocytosis, the HDL particle is degraded within the cell, and its constituent parts, including cholesterol and apolipoproteins, are catabolized. This degradation step completes the clearance process and allows for recycling or excretion of HDL components.
Regulation by microRNAs
In simple terms: Small RNA molecules can tune how fast HDL is cleared.
MicroRNAs (miRNAs) have been shown to regulate high-density lipoprotein metabolism, including pathways that influence HDL clearance. These small non-coding RNAs can modulate the expression of genes involved in HDL uptake and degradation, thereby affecting plasma HDL levels.
Impact of metabolic and pharmacological factors
In simple terms: Conditions like obesity and drugs like statins can change HDL clearance.
Obesity has been reported to affect HDL metabolism, which may include alterations in clearance rates. Statins, which are widely used to lower cholesterol, also influence HDL metabolism and can modulate HDL clearance pathways. These factors highlight the dynamic regulation of GO:0034384 in health and disease.
Key Genes Involved in GO:0034384 high-density lipoprotein particle clearance
The following genes and proteins have been experimentally linked to high-density lipoprotein particle clearance or its regulation.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CUBN | Cubilin acts as a high-density lipoprotein receptor mediating HDL endocytosis | Key receptor for studying HDL clearance mechanisms |
| APOA1 | Major apolipoprotein component of HDL particles | Target for HDL function and clearance studies |
| SCARB1 | Scavenger receptor class B member 1 involved in HDL cholesterol uptake | Relevant to HDL metabolism and reverse cholesterol transport |
| ABCA1 | Mediates cholesterol efflux to form HDL particles | Impacts HDL biogenesis and subsequent clearance |
| ABCG1 | Facilitates cholesterol efflux to HDL | Linked to HDL metabolism and clearance |
| CETP | Cholesteryl ester transfer protein modulates HDL composition | Affects HDL levels and clearance dynamics |
| LCAT | Lecithin-cholesterol acyltransferase esterifies cholesterol on HDL | Influences HDL maturation and clearance |
| SR-BI | Scavenger receptor BI mediates selective HDL cholesterol uptake | Key for HDL clearance and reverse cholesterol transport |
| miRNAs (e.g., miR-33) | Regulate genes involved in HDL metabolism | Potential therapeutic targets for modulating HDL clearance |
| HMGCR | Target of statins, indirectly affects HDL metabolism | Statins modulate HDL clearance pathways |
| LIPC | Hepatic lipase remodels HDL particles | Affects HDL clearance and metabolism |
| PLTP | Phospholipid transfer protein modulates HDL size and composition | Impacts HDL clearance |
| APOM | Apolipoprotein M associated with HDL | May influence HDL function and clearance |
| SAA | Serum amyloid A can associate with HDL during inflammation | Links inflammation to HDL clearance |
| PON1 | Paraoxonase 1 is associated with HDL and has antioxidant properties | Relevant to HDL function and clearance |
| MPO | Myeloperoxidase can modify HDL and affect its clearance | Inflammatory modification of HDL |
| CUBILIN | Alternative name for CUBN | HDL receptor |
How Is high-density lipoprotein particle clearance Regulated?
High-density lipoprotein particle clearance is regulated at multiple levels. MicroRNAs, such as those reviewed by Baldán et al., can modulate the expression of genes involved in HDL metabolism, thereby affecting clearance rates. Statins, which inhibit HMG-CoA reductase, have been shown to influence HDL metabolism, potentially altering clearance pathways. Obesity is associated with changes in HDL metabolism that may impact clearance. Additionally, inflammatory conditions can modify HDL particles, for example through serum amyloid A or myeloperoxidase, which may affect their recognition and clearance. These regulatory mechanisms ensure that HDL levels are maintained within a physiological range and can adapt to metabolic and inflammatory challenges.
high-density lipoprotein particle clearance and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CUBN | HDL clearance and kidney function | CUBN knockout cell lines or animal models |
| APOA1 | Atherosclerosis and HDL deficiency | APOA1 transgenic or knockout mice |
| SCARB1 | Cardiovascular disease and HDL uptake | SCARB1 knockout models |
| CETP | Dyslipidemia and HDL levels | CETP transgenic models |
| LCAT | Fish-eye disease and HDL metabolism | LCAT knockout models |
Atherosclerosis and cardiovascular disease
HDL is well known for its antiatherogenic role, and its clearance influences plasma HDL-cholesterol levels. Alterations in HDL clearance can affect reverse cholesterol transport and thus cardiovascular risk. Statins, which modulate HDL metabolism, are used to reduce cardiovascular events, partly through effects on HDL.
Sepsis and infection
HDL particles act as scavengers for bacterial components, and reconstituted HDL therapy improves survival in mouse models of sepsis. The clearance of HDL may therefore impact the ability of HDL to neutralize pathogens and modulate innate immunity.
Obesity and metabolic syndrome
Obesity affects HDL metabolism, potentially including clearance pathways. This link suggests that dysregulated HDL clearance may contribute to the low HDL-cholesterol levels often observed in obese individuals.
Blood-brain barrier function
Recent insights suggest that HDL regulates blood-brain barrier function, and clearance mechanisms may influence this process. This connection expands the relevance of HDL clearance to neurological and cerebrovascular biology.
From high-density lipoprotein particle clearance-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does CUBN mediate HDL clearance in vivo? | CUBN knockout mouse or cell line |
| How do miRNAs regulate HDL clearance? | miRNA overexpression or knockout cell models |
| What is the effect of statins on HDL clearance? | Statin-treated cell or animal models |
| How does obesity alter HDL clearance? | Diet-induced obesity mouse models |
| Can reconstituted HDL improve sepsis survival? | Mouse sepsis models treated with rHDL |
| Does HDL clearance affect blood-brain barrier? | In vitro BBB models with HDL treatment |
How to Study the high-density lipoprotein particle clearance Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radiolabeled HDL uptake | Receptor-mediated endocytosis rate | CUBN-mediated HDL clearance |
| Fluorescent HDL binding | Cell surface binding and internalization | High-throughput screening |
| CRISPR knockout | Gene function in HDL clearance | CUBN, SCARB1, etc. |
| miRNA mimic/inhibitor | Regulation of HDL clearance genes | miR-33 studies |
| Lipoprotein profiling | HDL-cholesterol levels | Statin or obesity studies |
| In vivo clearance assay | HDL half-life in circulation | Sepsis models |
| Blood-brain barrier permeability | HDL effects on BBB | Neurological studies |
| Proteomics | HDL-associated proteins | HDL composition analysis |
Receptor binding and uptake assays
To study HDL clearance, researchers can use radiolabeled or fluorescently labeled HDL particles to measure binding and internalization in cells expressing candidate receptors such as cubilin. These assays quantify the rate of receptor-mediated endocytosis and can be combined with competition experiments to confirm specificity.
Genetic manipulation and knockout models
CRISPR-Cas9 knockout of candidate genes (e.g., CUBN) in cell lines or animal models allows direct testing of their role in HDL clearance. Overexpression or knockdown of miRNAs can reveal regulatory mechanisms.
Lipid and lipoprotein profiling
Measuring plasma HDL-cholesterol and apolipoprotein levels in response to genetic or pharmacological interventions provides functional readouts of clearance. Techniques such as FPLC or ultracentrifugation can separate lipoprotein fractions.
In vivo clearance studies
In animal models, HDL clearance can be assessed by injecting labeled HDL and monitoring its disappearance from circulation over time. Such studies are valuable for understanding the impact of sepsis, obesity, or statin treatment on HDL catabolism.
How CRISPR Can Be Used to Study GO:0034384 high-density lipoprotein particle clearance
Knockout
CRISPR knockout of CUBN or other candidate receptors can definitively test their requirement for HDL clearance. Knockout cell lines or mice lacking CUBN would be expected to show impaired HDL uptake and altered plasma HDL levels.
Point Mutation
Introducing point mutations in the HDL-binding domain of CUBN or other receptors can dissect the molecular determinants of HDL recognition and endocytosis. Such models help distinguish binding from internalization defects.
Knock-in
Knock-in of tagged versions of CUBN or APOA1 allows tracking of HDL particles and receptors in live cells. This approach can reveal trafficking pathways and clearance kinetics.
Overexpression
Overexpression of CUBN or other HDL receptors can enhance HDL clearance in cell models, providing a gain-of-function system to study regulation. Conversely, overexpression of miRNAs can suppress clearance pathways.
How EDITGENE Supports high-density lipoprotein particle clearance Research
Researchers studying high-density lipoprotein particle clearance-related genes often need to determine whether a candidate gene is causally involved in HDL uptake, degradation, or regulation. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this research, from generating knockout cell lines to performing high-throughput library screens.
Contact EDITGENE today to design your custom CRISPR model for high-density lipoprotein particle clearance research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| APOE Knockout HEK293 Cell Line | EDJ-KQ172 | Human | 348 | Details Get a Quote |
| LDLR Knockout HEK293 Cell Line | EDJ-KQ273 | Human | 3949 | Details Get a Quote |
| APOA1 Knockout HEK293 Cell Line | EDJ-KQ1462 | Human | 335 | Details Get a Quote |
| SCARB1 Knockout HEK293 Cell Line | EDJ-KQ2450 | Human | 949 | Details Get a Quote |
| APOA2 Knockout HEK293 Cell Line | EDJ-KQ4066 | Human | 336 | Details Get a Quote |
| APOM Knockout HEK293 Cell Line | EDJ-KQ12396 | Human | 55937 | Details Get a Quote |
| SCARB1 Knockout A-549 Cell Line | EDJ-KQ22977 | Human | 949 | Details Get a Quote |
| SCARB1 Knockout HCT 116 Cell Line | EDJ-KQ22978 | Human | 949 | Details Get a Quote |
| SCARB1 Knockout HeLa Cell Line | EDJ-KQ22979 | Human | 949 | Details Get a Quote |
| APOA2 Knockout HCT 116 Cell Line | EDJ-KQ25098 | Human | 336 | Details Get a Quote |
| LDLR Knockout HCT 116 Cell Line | EDJ-KQ43957 | Human | 3949 | Details Get a Quote |
| LDLR Knockout HeLa Cell Line | EDJ-KQ43958 | Human | 3949 | Details Get a Quote |
| APOE Knockout A-549 Cell Line | EDJ-KQ41271 | Human | 348 | Details Get a Quote |
| APOE Knockout HCT 116 Cell Line | EDJ-KQ41272 | Human | 348 | Details Get a Quote |
| APOE Knockout HeLa Cell Line | EDJ-KQ41273 | Human | 348 | Details Get a Quote |
Displaying Records 1 To 15 Of 34 Records
- 1
- 2
- Next Page »
Frequently Asked Questions About high-density lipoprotein particle clearance
What is GO:0034384?
GO:0034384 is the Gene Ontology term for high-density lipoprotein particle clearance, the process by which HDL particles are removed from the blood via receptor-mediated endocytosis and degraded.
What is high-density lipoprotein particle clearance?
It is the biological process of removing HDL particles from circulation through receptor-mediated endocytosis and subsequent degradation of their components.
What genes are involved in high-density lipoprotein particle clearance?
Key genes include CUBN (cubilin), APOA1, SCARB1, ABCA1, ABCG1, CETP, LCAT, and various miRNAs that regulate HDL metabolism.
How is HDL clearance regulated?
HDL clearance is regulated by miRNAs, statins, obesity status, and inflammatory mediators that can modify HDL particles.
What diseases are associated with HDL clearance?
Alterations in HDL clearance have been linked to atherosclerosis, sepsis, obesity, and blood-brain barrier dysfunction.
What is the role of cubilin in HDL clearance?
Cubilin (CUBN) acts as a high-density lipoprotein receptor that mediates the endocytosis of HDL particles.
Can CRISPR be used to study HDL clearance?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models can be used to study genes involved in HDL clearance.
What methods are used to measure HDL clearance?
Common methods include radiolabeled HDL uptake assays, fluorescent binding assays, lipoprotein profiling, and in vivo clearance studies.
How does obesity affect HDL clearance?
Obesity has been reported to affect HDL metabolism, which may include changes in clearance rates.
What is the link between HDL clearance and sepsis?
HDL particles scavenge bacterial components, and reconstituted HDL therapy improves survival in sepsis models, suggesting clearance impacts infection outcomes.
Conclusion
High-density lipoprotein particle clearance (GO:0034384) is a fundamental biological process that controls plasma HDL levels and influences cardiovascular, metabolic, and immune functions. The identification of cubilin as an HDL receptor and the discovery of miRNA-based regulation have provided mechanistic insights into this process. Dysregulation of HDL clearance is associated with atherosclerosis, sepsis, obesity, and blood-brain barrier dysfunction, making it a compelling target for therapeutic intervention. Continued research using CRISPR models and advanced screening methods will further elucidate the molecular players and regulatory networks governing HDL clearance.
References
- 1. Baldán Á et al.. 2016. miRNAs and High-Density Lipoprotein metabolism.. Biochim Biophys Acta 1861(12 Pt B):2053-2061 PMID: 26869447
- 2. Meilhac O et al.. 2020. High-Density Lipoproteins Are Bug Scavengers.. Biomolecules 10(4) PMID: 32290632
- 3. Moestrup SK et al.. 2000. Cubilin, a high-density lipoprotein receptor.. Curr Opin Lipidol 11(2):133-40 PMID: 10787174
- 4. Zhu P et al.. 2025. Mechanisms of high-density lipoprotein in regulating blood-brain barrier function: insights and implications.. Fluids Barriers CNS 22(1):113 PMID: 41194222
- 5. Tanaka S et al.. 2020. Reconstituted High-density Lipoprotein Therapy Improves Survival in Mouse Models of Sepsis.. Anesthesiology 132(4):825-838 PMID: 32101976
- 6. Sviridov D et al.. 2007. Statins and metabolism of high density lipoprotein.. Cardiovasc Hematol Agents Med Chem 5(3):215-21 PMID: 17630948
- 7. Rashid S et al.. 2007. Effect of obesity on high-density lipoprotein metabolism.. Obesity (Silver Spring) 15(12):2875-88 PMID: 18198293
- 8. Kwiterovich PO Jr. 1998. The antiatherogenic role of high-density lipoprotein cholesterol.. Am J Cardiol 82(9A):13Q-21Q PMID: 9819099
